Ribbon Biolabs Raises EUR 18 Million Series A Financing

Funds Enabling Commercial Scale Production Facilities and US Expansion for DNA Synthesis Technology

02-Feb-2022 - Austria
Ribbon Biolabs, the DNA synthesis company, announced the successful close of EUR 18 million in its Series A funding round from a consortium of European and US investors led by Hadean Ventures and with participation from Lansdowne Partners, Helicase Venture as well as several undisclosed investors. Existing investors IST cube and tecnet equity also joined in the round.
pixabay.com

Symbolic image

The funds will be used for the commercialization of Ribbon Biolabs’ DNA synthesis technology, which uses an innovative approach integrating combinatorial optimization algorithms to guide the automated enzymatic assembly of DNA. This includes the setup of production facilities with key technology partners and the preparation for expansion into the US market. The investment will also support Ribbon Biolabs’ ambitious recruitment plans as it continues to grow its team including key operational and scientific positions located at the company’s facilities in Vienna and in the IST Park, the technology park of the prestigious Institute of Science and Technology – IST Austria.
“We are more than excited and proud about this close as this fundraising enables us to expand our production capabilities and collaborate with key partners,” commented Harold P. de Vladar, CEO and founder of Ribbon Biolabs. “I value the financial commitment from both our existing investors and new life science specialists as we grow our company and empower a new era of synthetic DNA production.”
Ribbon Biolabs was founded in 2018 to redefine the potential of synthetic DNA. The technology addresses the growing market need for synthetic DNA of sub-genomic size, an essential component for developments in biopharmaceutical research and key for the disruptive potential of synthetic biology. The company recently validated its capabilities by providing a synthetic DNA molecule of 10,000 base pairs (bp) in May 2021. In December 2021, the company extended this success by synthesizing a 20,000 bp molecule.
Walter Stockinger, Managing Partner at Hadean Ventures added: “Synthetic biology is about to disrupt the biopharmaceutical and other life science industries by overcoming previous limitations with new genetic technologies. We are excited to support Ribbon Biolabs in its mission to fully automate long DNA synthesis through its novel and proprietary approach and to become an important player in this new field of biology.”

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

Something is happening in the life science industry ...

This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.